Search
Hycanthone
go.drugbank.com/drugs/DB14061ExperimentalPotentially toxic, but effective antischistosomal agent, it is a metabolite of LUCANTHONE. Hycanthone was approved by the FDA in 1975 but is no longer used.
Voclosporin
go.drugbank.com/drugs/DB11693ApprovedInvestigationalEarly intervention with voclosporin coupled with a kidney response is believed to prevent irreversible damage to the kidney and lead to better long-term clinical outcomes for patients with LN. … [L31218] This [cyclosporine] A analog was approved by the FDA on January 22, 2021 following promising results in clinical trials.
Nusinersen
go.drugbank.com/drugs/DB13161ApprovedInvestigationalAn antisense oligonucleotide that induces survival motor neuron (SMN) protein expression, it was approved by the U.S.
Cimetidine
go.drugbank.com/drugs/DB00501ApprovedInvestigationalA histamine congener, it competitively inhibits histamine binding to histamine H2 receptors. Cimetidine has a range of pharmacological actions.
Phosphocreatine
go.drugbank.com/drugs/DB13191InvestigationalNutraceuticalIt is primarily found endogenously in the skeletal muscles of vertebrates where it serves a critical role as a rapidly acting energy buffer for muscle cell actions like contractions via its ability to
Dyclonine
go.drugbank.com/drugs/DB00645ApprovedInvestigationalDyclonine is an oral anaesthetic found in Sucrets, an over the counter throat lozenge. It may also be found in some Cepacol sore throat spray products.
Temoporfin
go.drugbank.com/drugs/DB11630ApprovedIt was first authorized for market by the European Medicines Agency in October 2001. It is currently available under the brand name Foscan.
Donanemab
go.drugbank.com/drugs/DB16647ApprovedInvestigational[L50988] It works to reduce amyloid beta plaques and impede the progression of AD.[L50988] … [A232214] On July 2, 2024, donanemab was approved by the FDA for the treatment of AD in patients with mild cognitive impairment or dementia symptoms.
NOX-100
go.drugbank.com/drugs/DB05799InvestigationalNOX-100 is the new nitric oxide (NO) neutralizing agent being developed by San Diego-based Medinox -- demonstrated its effectiveness and potential as a therapeutic to treat hemorrhagic shock. … NOX-100 is the first in a series of proprietary NO neutralizing compounds Medinox is developing to bind and inactivate NO, a simple gas molecule that is a key biological messenger in the body.